Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Last trade$8.83
Day change-$0.085 (-0.95%)
Day range$7.85 – $9.52
Volume14,343
Market cap$41M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$40.75M
Price / earnings
—
Price / book
7.98×
Price / sales
0.46×
EV / sales
0.82×
EV / EBITDA
21.26×
Profitability
Earnings per share
-$2.58
Return on assets
-15.68%
Return on equity
-231.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
7.28×
Current ratio
1.76×
Quick ratio
0.86×
Cash ratio
0.19×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.17M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HBIO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$22.2M
$22.73M
$20.76M
$23.74M
$20.59M
$20.45M
$21.77M
$24.56M
Cost of revenue
$9.89M
$10.1M
$8.51M
$9.56M
$8.57M
$8.92M
$9.59M
$10.55M
Gross profit
$12.31M
$12.63M
$12.24M
$14.17M
$12.02M
$11.53M
$12.18M
$14.01M
Selling, general and administrative
$10.18M
$10.02M
$10.04M
$9.21M
$8.79M
$8.8M
$10.16M
$10.2M
Research and development
$2.26M
$2.45M
$2.33M
$2.18M
$2.13M
$2.19M
$2.32M
$2.33M
Total operating expenses
$13.46M
$13.61M
$13.42M
$12.46M
$11.82M
$12.35M
$61.85M
$14M
Operating income
-$1.15M
-$978K
-$1.17M
$1.71M
$197K
-$819K
-$49.67M
$11K
Interest expense
-$1.78M
-$1.79M
$0
$0
-$1.32M
-$1M
$0
$0
Income before taxes
-$2.7M
-$2.9M
-$3.31M
-$3.2M
-$1.13M
-$2.25M
-$50.79M
$590K
Income taxes
-$72K
$14K
$117K
-$357K
$97K
$28K
-$454K
$572K
Net income
-$2.62M
-$2.91M
-$3.42M
-$2.85M
-$1.23M
-$2.28M
-$50.34M
$18K
Net income attributable to common shareholders
-$2.62M
-$2.91M
-$3.42M
-$2.85M
-$1.23M
-$2.28M
-$50.34M
$18K
EBITDA
-$198K
$397K
$176K
$3.06M
$1.52M
$797K
-$62K
$1.77M
Basic earnings per share
-$0.58
-$0.64
-$0.77
-$0.64
-$0.28
-$0.52
-$11.42
$0.00
Diluted earnings per share
-$0.58
-$0.64
-$0.77
-$0.64
-$0.28
-$0.52
-$11.42
$0.00
Recent news
Company coverage with links to the original publishers.
The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.
Harvard Bioscience reported Q2 2025 GAAP revenue of $20.5 million, exceeding analyst expectations by 9.3% despite an 11.3% year-over-year decline. The company showed improved operational cash flow and continued focus on new product development in biomedical research technologies.
Harvard Bioscience announced the appointment of John Duke to its board of directors and the retirement of Thomas Loewald. The company also reported its first quarter 2025 financial results.
Harvard Bioscience reported Q1 2025 results with revenues of $21.8 million, down from $24.5 million in Q1 2024. The company recorded a net loss of $50.3 million, which included a $48 million goodwill impairment. Adjusted EBITDA was $0.8 million, down from $1.6 million in the prior year quarter.
Harvard Bioscience announced the resignation of its Chief Financial Officer Jennifer Cote, effective upon the filing of the company's Q1 2025 report. The company has appointed Mark Frost as Interim CFO, who brings over 30 years of financial and executive experience.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.